ArticleJournal of experimental pharmacology2025
Antidiabetic Effect of Hydro-Ethanolic Leaf Extract of
Article in Journal of experimental pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential Impact ofAntioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetes mellitus, characterized by chronic hyperglycaemia, remains a major global health burden. Limitations of conventional therapies have led to growing interest in medicinal plants like Methods: The extract was tested at 25-200 mg/kg in an oral glucose tolerance test (OGTT), and at 100-400 mg/kg in normoglycemic and high fructose-fed, streptozotocin (STZ)-induced type 2 diabetic rats over 21 and 28 days, respectively. Fasting blood glucose, insulin, glycated haemoglobin (HbA1c), glucose transporter type 4 (GLUT4), haematological and biochemical parameters, and histopathological changes in key organs were evaluated. Results: In the OGTT, the extract significantly reduced postprandial blood glucose at 100 and 200 mg/kg starting from 60 minutes post-glucose load (p < 0.05). In normoglycemic rats, repeated administration over 21 days led to a dose-dependent and statistically significant reduction in fasting blood glucose beginning on day 14 and sustained through day 21 (p < 0.01). In diabetic rats, fasting blood glucose levels were significantly reduced from day 7 onward, with 400 mg/kg producing effects comparable to glibenclamide by day 28 (p < 0.01). Insulin, GLUT4, and HbA1c levels were not significantly altered (p > 0.05). Haematological and biochemical parameters remained within normal ranges, and histopathological examination showed preservation of pancreatic and renal tissues in treated groups. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.